CyFlow CD90 PE
品番 | AF411705 | ||
---|---|---|---|
抗体名 | Anti-Hu CD90 PE,5E10 | ||
包装単位 | 100 tests | ||
濃度 | - | ||
容量 | 1 ml | ||
関連製品 (アイソタイプコントロール) |
Mouse IgG1 PE (BV655324) |
||
反応性|交差吸着 | Human | Non-Human Primates | Pig | Dog | レーザー | Blue, Green, Yellow |
抗原 | CD90, THY-1 | 最大蛍光波長 | 576 nm |
クローン | 5E10 | 最大励起波長 | 496 nm, 565 nm |
ホスト | Mouse | 標識/Format | PE |
アイソタイプ | IgG1 | 研究分野 | Immunophenotyping |
クローナリティ | monoclonal | 用途 | Flow cytometry |
Anti-Hu CD90 PE,5E10
特異性
The mouse monoclonal antibody 5E10 recognizes CD90 antigen, a GPI-anchored cell surface glycoprotein expressed predominantly on thymocytes, hematopoietic stem cells and neurons.
抗原情報
CD90 (Thy-1) is an 18-35 kDa GPI-anchored plasma membrane glycoprotein expressed in many cell types, such as in hematopoietic cells and neurons, connective tissues, various fibroblast and stromal cell lines, tumor endothelial cell lines and other. It is involved in T cell activation, cellular adhesion, proliferation and migration, neurite outgrowth, wound healing, apoptosis, and fibrosis. CD90 participates in multiple signaling cascades and its effects are tissue- and cell type-specific. It often functions as an important regulator of cell-cell and cell-matrix interactions.
利用方法
The reagent is designed for Flow Cytometry analysis of human blood cells. Recommended usage is 10 µl reagent / 100 µl of whole blood or 10^6 cells in a suspension. The content of a vial (1 ml) is sufficient for 100 tests.
保存方法
Avoid prolonged exposure to light. Store in the dark at 2-8°C. Do not freeze.
安定性情報
Do not use after expiration date stamped on vial label.
レファレンス
• Carlsten M, Björkström NK, Norell H, Bryceson Y, van Hall T, Baumann BC, Hanson M, Schedvins K, Kiessling R, Ljunggren HG, Malmberg KJ: DNAX accessory molecule‑1 mediated recognition of freshly isolated ovarian carcinoma by resting natural killer cells. Cancer·Res. 2007·Feb·1; 67(3):1317‑25. <·PMID:·17283169·>
• Chin-Yee IH, Keeney M, Stewart AK, Belch A, Bence-Buckler I, Couban S, Howson-Jan K, Rubinger M, Stewart D, Sutherland R, Paragamian V, Bhatia M, Foley R: Optimising parameters for peripheral blood leukapheresis after r‑metHuG‑CSF (filgrastim) and r‑metHuSCF (ancestim) in patients withmultiple myeloma: a temporal analysis of CD34(+) absolute counts and subsets. Bone·Marrow·Transplant. 2002·Dec; 30(12):851‑60. <·PMID:·12476276·>
• Hoppstädter J, Diesel B, Zarbock R, Breinig T, Monz D, Koch M, Meyerhans A, Gortner L, Lehr CM, Huwer H, Kiemer AK: Differential cell reaction upon Toll‑like receptor 4 and 9 activation in human alveolar and lung interstitial macrophages. Respir·Res. 2010·Sep·15; 11:124. <·PMID:·20843333·>
• Ito T, Inaba M, Inaba K, Toki J, Sogo S, Iguchi T, Adachi Y, Yamaguchi K, Amakawa R, Valladeau J, Saeland S, Fukuhara S, Ikehara S: A CD1a+/CD11c+ subset of human blood dendritic cells is a direct precursor of Langerhans cells. J·Immunol. 1999·Aug·1; 163(3):1409‑19. <·PMID:·10415041·>
• Kroeze KL, Jurgens WJ, Doulabi BZ, van Milligen FJ, Scheper RJ, Gibbs S: Chemokine‑mediated migration of skin‑derived stem cells: predominant role for CCL5/RANTES. J·Invest·Dermatol. 2009·Jun; 129(6):1569‑81. <·PMID:·19122644·>
• Seiffert M, Brossart P, Cant C, Cella M, Colonna M, Brugger W, Kanz L, Ullrich A, Bühring HJ: Signal‑regulatory protein alpha (SIRPalpha) but not SIRPbeta is involved in T‑cell activation, binds to CD47 with high affinity, and is expressed on immature CD34(+)CD38(‑) hematopoietic cells. Blood. 2001·May·1; 97(9):2741‑9. <·PMID:·11313266·>
• St Louis DC, Woodcock JB, Franzoso G, Blair PJ, Carlson LM, Murillo M, Wells MR, Williams AJ, Smoot DS, Kaushal S, Grimes JL, Harlan DM, Chute JP, June CH, Siebenlist U, Lee KP: Evidence for distinct intracellular signaling pathways in CD34+ progenitor to dendritic cell differentiationfrom a human cell line model. J·Immunol. 1999·Mar·15; 162(6):3237‑48. <·PMID:·10092775·>
Available Safety Data Sheets
CyFlow™ monoclonal antibodies SDS CA EN